Login to Your Account



In The Clinic NEWS

Trevena Inc. reported top-line results from its pivotal phase III APOLLO-1 and -2 efficacy studies of lead candidate oliceridine in moderate to severe acute pain following bunionectomy and abdominoplasty, respectively.

The endpoint miss in phase II with a topical version for moderate to severe acute vulvovaginal candidiasis (VVC, often known as yeast infection) did not dim Cidara Therapeutics Inc.'s optimism for an intravenous (I.V.) form of the echinocandin antifungal CD101 in candidemia, though Wall Street apparently felt otherwise.

SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med) and its partner, Astrazeneca plc, of London, shared phase II safety and efficacy data for savolitinib in patients with PRCC, a fatal form of kidney cancer.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: